Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
|Videos|September 5, 2017
Dr. Brawer on the Results of the Prolaris Test for Patients Prostate Cancer
Author(s)Michael Brawer, MD
Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the results of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
Advertisement
Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the results of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
It has been known for a long time that African-American men not only have more prostate cancer, but also have worse prostate cancer for reasons that are still unknown, states Brawer.
Ongoing studies are attempting to determine if there are biological differences that cause this increase in cancer, explains Brawer.
Advertisement
Related to this article
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.
Advertisement
Advertisement
Trending on OncLive
1
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
2
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
3
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
4
Dr Forde on Selecting Neoadjuvant and Perioperative Immunotherapy in Resectable NSCLC
5